Pfizer Takes ‘Opportunistic’ Approach To Future Biosimilars

Company Sees 93% Growth In Biosimilars Business To $559m In Q2

 
• By Akriti Seth
  
Growth
Pfizer has seen growth in both biosimilars and sterile injectables business • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products